VX765 is a Caspase-1 inhibitor that not only inhibits the downstream pyroptotic pathway of Caspase-1 (including reducing the expression of the pro-inflammatory factor IL-1 and the pore-forming protein N-GSDMD), but also inhibits ASC oligomerization, which helps to reduce neurological damage after stroke. This evidence concerns the gene IL1B and stroke disorder.